Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024
Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024
Attendees interested in learning more about the Company and its products, including its upcoming Co-Dx PCR platform, are invited to visit Booth #3 D15-1. To learn more about the fair, visit .SALT LAKE CITY, Nov. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth and delivering a presentation at the MEDICA 2024 trade fair in Düsseldorf, Germany on November 11-14.
2024年11月5日，科診公司（Co-Diagnostics, Inc.）（納斯達克-CM: CODX）（"公司"或"Co-Dx"）是一家分子診斷公司，擁有一項獨特的，用於開發分子診斷試劑的專利平台。今天宣佈，將在德國杜塞爾多夫舉辦的MEDICA 2024交易展會上設立展臺並進行演講，展會時間爲11月11日至14日。
MEDICA has become the largest medical B2B trade fair in the world, attracting 83,000 visitors and over 5,300 exhibitors from almost 70 countries. The Company expects to use the opportunity to generate increased interest in its suite of PCR in vitro diagnostic and research products for infectious diseases, and to introduce and promote its Co-Primers technology and applications to a wide audience of international attendees.
MEDICA已成爲世界上規模最大的醫療20億交易展會，吸引了來自近70個國家的83,000名參觀者和超過5,300家參展商。公司希望利用這個機會，爲其用於傳染性疾病PCR體外診斷和研究產品套件產生更多興趣，並向國際與會者廣泛介紹和推廣其Co-Primers技術和應用。
The Company's presentation on its upcoming Co-Dx PCR platform*, titled "Advancing POC/OTC Diagnostics: Innovations in Test Development for the Co-Dx PCR Platform" will take place in Hall 8A Booth G40 on Wednesday, November 13 at 12:05 PM CET.
公司即將推出的Co-Dx PCR平台*的演示主題爲"推進POC/OTC診斷：Co-Dx PCR平台檢測開發的創新"，將於11月13日星期三下午12:05在8A展廳G40展位舉行。
Attendees interested in learning more about the Company and its products, including its upcoming Co-Dx PCR platform, are invited to visit Booth #3 D15-1. To learn more about the fair, visit .
有興趣了解公司及其產品（包括即將推出的Co-Dx PCR平台）的與會者，歡迎參觀展位＃3 D15-1。了解更多關於展會的信息，請訪問。
*The Co-Dx PCR platform (including the Co-Dx PCR Home, Co-Dx PCR Pro, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.
*Co-Dx PCR平台（包括Co-Dx PCR Home、Co-Dx PCR Pro、移動應用程序以及所有相關測試和軟件）正在接受FDA和/或其他監管機構審查，目前不可出售。Co-Dx PCR Pro儀器和Co-Dx COVID-19測試目前正在接受FDA審查。
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.
關於Co-Diagnostics，Inc.：
Co-Diagnostics，Inc.是一家總部位於猶他州的分子診斷公司，開發，製造和銷售最先進的診斷技術。該公司的技術廣泛應用於基於核酸分子（DNA或RNA）的檢測和/或分析設計的測試。公司還利用自有技術爲其Co-Dx PCR在家和點-of-care平台設計特定測試，並尋找用於除傳染性疾病以外應用的遺傳標記。
SOURCE Co-Diagnostics
資料來源：Co-Diagnostics
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
